Agile Therapeutics Inc (NASDAQ:AGRX) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 370,069 shares, a drop of 39.2% from the February 15th total of 608,602 shares. Based on an average daily volume of 55,534 shares, the short-interest ratio is presently 6.7 days. Currently, 3.3% of the shares of the company are short sold.
A number of hedge funds and other institutional investors have recently made changes to their positions in AGRX. Bank of New York Mellon Corp raised its holdings in Agile Therapeutics by 113.1% in the 4th quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 20,654 shares in the last quarter. Royal Bank of Canada raised its holdings in Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after acquiring an additional 27,907 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in Agile Therapeutics in the 3rd quarter valued at $161,000. Goldman Sachs Group Inc. acquired a new position in Agile Therapeutics in the 2nd quarter valued at $309,000. Finally, Dimensional Fund Advisors LP raised its holdings in Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after acquiring an additional 82,213 shares in the last quarter. 67.34% of the stock is owned by hedge funds and other institutional investors.
Agile Therapeutics (NASDAQ:AGRX) opened at $3.64 on Tuesday. The firm has a market capitalization of $124.44, a price-to-earnings ratio of -3.96 and a beta of 1.91. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a fifty-two week low of $1.93 and a fifty-two week high of $5.60.
ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/13/agile-therapeutics-inc-agrx-sees-significant-decline-in-short-interest.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.